(EW) Edwards Lifesciences - Ratings and Ratios
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US28176E1082
Valve Replacement, Valve Repair, Surgical Valves
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 27.3% |
| Value at Risk 5%th | 37.9% |
| Relative Tail Risk | -15.70% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.73 |
| Alpha | 11.37 |
| CAGR/Max DD | 0.11 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.472 |
| Beta | 0.523 |
| Beta Downside | 0.550 |
| Drawdowns 3y | |
|---|---|
| Max DD | 37.53% |
| Mean DD | 16.19% |
| Median DD | 18.69% |
Description: EW Edwards Lifesciences September 29, 2025
Edwards Lifesciences (NYSE:EW) develops and sells minimally invasive cardiovascular devices, including the transcatheter aortic valve replacement (TAVR) SAPIEN system, the mitral/tricuspid repair platforms PASCAL PRECISION and Cardioband, and a suite of surgical structural-heart products under the INSPIRIS brand such as RESILIA tissue valves and the KONECT conduit. The firm markets its portfolio worldwide through a direct sales force and independent distributors, and has been operating since 1958 from its Irvine, California headquarters.
Key recent metrics: FY 2023 revenue reached approximately $5.2 billion, driven by a 12 % year-over-year increase in TAVR sales, which now represent roughly 45 % of the U.S. TAVR market share. The company’s pipeline includes next-generation RESILIA tissue technologies that aim to extend valve durability, a critical factor as the aging global population (projected to exceed 1.5 billion people over 65 by 2030) fuels demand for less invasive cardiac interventions. A material economic driver is Medicare’s evolving reimbursement policy for TAVR, which can materially affect pricing power and adoption rates.
For a deeper, data-rich analysis of EW’s valuation dynamics, consider exploring the detailed metrics and scenario models available on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income (1.36b TTM) > 0 and > 6% of Revenue (6% = 353.0m TTM) |
| FCFTA 0.09 (>2.0%) and ΔFCFTA 5.21pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 81.09% (prev 89.64%; Δ -8.55pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.11 (>3.0%) and CFO 1.42b > Net Income 1.36b (YES >=105%, WARN >=100%) |
| Net Debt (-1.99b) to EBITDA (1.74b) ratio: -1.14 <= 3.0 (WARN <= 3.5) |
| Current Ratio 4.00 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (585.7m) change vs 12m ago -2.07% (target <= -2.0% for YES) |
| Gross Margin 78.22% (prev 79.37%; Δ -1.15pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 44.84% (prev 41.14%; Δ 3.70pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 80.08 (EBITDA TTM 1.74b / Interest Expense TTM 19.8m) >= 6 (WARN >= 3) |
Altman Z'' 11.63
| (A) 0.36 = (Total Current Assets 6.36b - Total Current Liabilities 1.59b) / Total Assets 13.27b |
| (B) 1.07 = Retained Earnings (Balance) 14.15b / Total Assets 13.27b |
| warn (B) unusual magnitude: 1.07 — check mapping/units |
| (C) 0.12 = EBIT TTM 1.59b / Avg Total Assets 13.12b |
| (D) 4.75 = Book Value of Equity 14.56b / Total Liabilities 3.07b |
| Total Rating: 11.63 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 76.58
| 1. Piotroski 6.50pt |
| 2. FCF Yield 2.59% |
| 3. FCF Margin 20.50% |
| 4. Debt/Equity 0.07 |
| 5. Debt/Ebitda -1.14 |
| 6. ROIC - WACC (= 4.43)% |
| 7. RoE 13.35% |
| 8. Rev. Trend 53.53% |
| 9. EPS Trend 59.80% |
What is the price of EW shares?
As of December 01, 2025, the stock is trading at USD 86.67 with a total of 1,317,527 shares traded.
Over the past week, the price has changed by +1.81%, over one month by +5.45%, over three months by +6.70% and over the past year by +21.47%.
Over the past week, the price has changed by +1.81%, over one month by +5.45%, over three months by +6.70% and over the past year by +21.47%.
Is EW a buy, sell or hold?
Edwards Lifesciences has received a consensus analysts rating of 3.69.
Therefor, it is recommend to hold EW.
- Strong Buy: 10
- Buy: 4
- Hold: 17
- Sell: 0
- Strong Sell: 1
What are the forecasts/targets for the EW price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 93.9 | 8.4% |
| Analysts Target Price | 93.9 | 8.4% |
| ValueRay Target Price | 92.3 | 6.5% |
EW Fundamental Data Overview November 26, 2025
Market Cap USD = 49.73b (49.73b USD * 1.0 USD.USD)
P/E Trailing = 37.1535
P/E Forward = 30.2115
P/S = 8.4526
P/B = 4.8409
P/EG = 4.8352
Beta = 0.973
Revenue TTM = 5.88b USD
EBIT TTM = 1.59b USD
EBITDA TTM = 1.74b USD
Long Term Debt = 598.2m USD (from longTermDebt, last quarter)
Short Term Debt = 26.8m USD (from shortTermDebt, last quarter)
Debt = 700.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -1.99b USD (from netDebt column, last quarter)
Enterprise Value = 46.59b USD (49.73b + Debt 700.3m - CCE 3.84b)
Interest Coverage Ratio = 80.08 (Ebit TTM 1.59b / Interest Expense TTM 19.8m)
FCF Yield = 2.59% (FCF TTM 1.21b / Enterprise Value 46.59b)
FCF Margin = 20.50% (FCF TTM 1.21b / Revenue TTM 5.88b)
Net Margin = 23.19% (Net Income TTM 1.36b / Revenue TTM 5.88b)
Gross Margin = 78.22% ((Revenue TTM 5.88b - Cost of Revenue TTM 1.28b) / Revenue TTM)
Gross Margin QoQ = 77.77% (prev 77.64%)
Tobins Q-Ratio = 3.51 (Enterprise Value 46.59b / Total Assets 13.27b)
Interest Expense / Debt = 2.83% (Interest Expense 19.8m / Debt 700.3m)
Taxrate = 16.10% (56.1m / 348.4m)
NOPAT = 1.33b (EBIT 1.59b * (1 - 16.10%))
Current Ratio = 4.00 (Total Current Assets 6.36b / Total Current Liabilities 1.59b)
Debt / Equity = 0.07 (Debt 700.3m / totalStockholderEquity, last quarter 10.21b)
Debt / EBITDA = -1.14 (Net Debt -1.99b / EBITDA 1.74b)
Debt / FCF = -1.65 (Net Debt -1.99b / FCF TTM 1.21b)
Total Stockholder Equity = 10.22b (last 4 quarters mean from totalStockholderEquity)
RoA = 10.28% (Net Income 1.36b / Total Assets 13.27b)
RoE = 13.35% (Net Income TTM 1.36b / Total Stockholder Equity 10.22b)
RoCE = 14.66% (EBIT 1.59b / Capital Employed (Equity 10.22b + L.T.Debt 598.2m))
RoIC = 12.30% (NOPAT 1.33b / Invested Capital 10.82b)
WACC = 7.86% (E(49.73b)/V(50.43b) * Re(7.94%) + D(700.3m)/V(50.43b) * Rd(2.83%) * (1-Tc(0.16)))
Discount Rate = 7.94% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -1.76%
[DCF Debug] Terminal Value 73.79% ; FCFE base≈924.4m ; Y1≈709.8m ; Y5≈444.0m
Fair Price DCF = 14.36 (DCF Value 8.33b / Shares Outstanding 580.3m; 5y FCF grow -27.59% → 3.0% )
EPS Correlation: 59.80 | EPS CAGR: 7.55% | SUE: 4.0 | # QB: 5
Revenue Correlation: 53.53 | Revenue CAGR: 4.23% | SUE: 0.31 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.68 | Chg30d=+0.017 | Revisions Net=+11 | Analysts=20
EPS current Year (2025-12-31): EPS=2.59 | Chg30d=+0.077 | Revisions Net=+29 | Growth EPS=+6.4% | Growth Revenue=+10.9%
EPS next Year (2026-12-31): EPS=2.86 | Chg30d=+0.073 | Revisions Net=+26 | Growth EPS=+10.8% | Growth Revenue=+9.8%
P/E Trailing = 37.1535
P/E Forward = 30.2115
P/S = 8.4526
P/B = 4.8409
P/EG = 4.8352
Beta = 0.973
Revenue TTM = 5.88b USD
EBIT TTM = 1.59b USD
EBITDA TTM = 1.74b USD
Long Term Debt = 598.2m USD (from longTermDebt, last quarter)
Short Term Debt = 26.8m USD (from shortTermDebt, last quarter)
Debt = 700.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -1.99b USD (from netDebt column, last quarter)
Enterprise Value = 46.59b USD (49.73b + Debt 700.3m - CCE 3.84b)
Interest Coverage Ratio = 80.08 (Ebit TTM 1.59b / Interest Expense TTM 19.8m)
FCF Yield = 2.59% (FCF TTM 1.21b / Enterprise Value 46.59b)
FCF Margin = 20.50% (FCF TTM 1.21b / Revenue TTM 5.88b)
Net Margin = 23.19% (Net Income TTM 1.36b / Revenue TTM 5.88b)
Gross Margin = 78.22% ((Revenue TTM 5.88b - Cost of Revenue TTM 1.28b) / Revenue TTM)
Gross Margin QoQ = 77.77% (prev 77.64%)
Tobins Q-Ratio = 3.51 (Enterprise Value 46.59b / Total Assets 13.27b)
Interest Expense / Debt = 2.83% (Interest Expense 19.8m / Debt 700.3m)
Taxrate = 16.10% (56.1m / 348.4m)
NOPAT = 1.33b (EBIT 1.59b * (1 - 16.10%))
Current Ratio = 4.00 (Total Current Assets 6.36b / Total Current Liabilities 1.59b)
Debt / Equity = 0.07 (Debt 700.3m / totalStockholderEquity, last quarter 10.21b)
Debt / EBITDA = -1.14 (Net Debt -1.99b / EBITDA 1.74b)
Debt / FCF = -1.65 (Net Debt -1.99b / FCF TTM 1.21b)
Total Stockholder Equity = 10.22b (last 4 quarters mean from totalStockholderEquity)
RoA = 10.28% (Net Income 1.36b / Total Assets 13.27b)
RoE = 13.35% (Net Income TTM 1.36b / Total Stockholder Equity 10.22b)
RoCE = 14.66% (EBIT 1.59b / Capital Employed (Equity 10.22b + L.T.Debt 598.2m))
RoIC = 12.30% (NOPAT 1.33b / Invested Capital 10.82b)
WACC = 7.86% (E(49.73b)/V(50.43b) * Re(7.94%) + D(700.3m)/V(50.43b) * Rd(2.83%) * (1-Tc(0.16)))
Discount Rate = 7.94% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -1.76%
[DCF Debug] Terminal Value 73.79% ; FCFE base≈924.4m ; Y1≈709.8m ; Y5≈444.0m
Fair Price DCF = 14.36 (DCF Value 8.33b / Shares Outstanding 580.3m; 5y FCF grow -27.59% → 3.0% )
EPS Correlation: 59.80 | EPS CAGR: 7.55% | SUE: 4.0 | # QB: 5
Revenue Correlation: 53.53 | Revenue CAGR: 4.23% | SUE: 0.31 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.68 | Chg30d=+0.017 | Revisions Net=+11 | Analysts=20
EPS current Year (2025-12-31): EPS=2.59 | Chg30d=+0.077 | Revisions Net=+29 | Growth EPS=+6.4% | Growth Revenue=+10.9%
EPS next Year (2026-12-31): EPS=2.86 | Chg30d=+0.073 | Revisions Net=+26 | Growth EPS=+10.8% | Growth Revenue=+9.8%
Additional Sources for EW Stock
News:
Wall Street Journal |
Benzinga |
Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle